



Procter & Gamble Hygiene  
and Health Care Limited  
CIN: L24239MH1964PLC012971  
Registered Office:  
P&G Plaza  
Cardinal Gracias Road, Chakala  
Andheri (E), Mumbai 400 099  
Tel: (91-22) 2826 6000  
Fax: (91-22) 2826 7303  
[www.pg.com/en\\_IN](http://www.pg.com/en_IN)

To,  
The Corporate Relations Department  
The BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400001

May 5, 2017

Ref:- Scrip Code:- 500459

Dear Sir / Madam,

**Sub: Outcome of the meeting of the Board of Directors of the Company**

We are pleased to inform you that a meeting of the Board of Directors of the Company held today, the Unaudited Financial Results for the quarter ended March 31, 2017 were approved.

We are enclosing herewith the following:

- a. Unaudited Financial Results for the quarter ended March 31, 2017
- b. Press Release
- c. Limited review report in respect of Unaudited Financial Results for the quarter ended March 31, 2017 furnished by Statutory Auditors of the Company.


We are pleased to further inform you that the Board of Directors of the Company at its meeting held today, *inter alia*, has declared a special interim dividend of ₹ 362/- per Equity Share (Nominal Value of ₹ 10/- each). The Board of Directors of the Company has fixed Thursday, May 18, 2017 as the record date for the purpose of payment of said interim dividend. The dividend shall be paid, between May 22, 2017 to June 4, 2017.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For Procter & Gamble Hygiene and Health Care Limited

  
Prashant Bhatnagar  
Chief Financial Officer





**Procter & Gamble Hygiene  
and Health Care Limited**  
CIN : L24239MH1964PLC012971  
Registered Office  
P&G Plaza  
Cardinal Gracias Road, Chakala  
Andheri (E), Mumbai 400 099  
(91 - 22) 2826 6000 phone  
(91 - 22) 2826 7303 fax  
www.pg.com/en\_IN/

Part I

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st MARCH 2017**

(₹ in Lakhs)

Particulars	(1)	(2)	(3)	(4)	(5)	(6)
	Three Months Ended 31st March 2017	Preceding Three Months Ended 31st December 2016	Corresponding Three Months Ended 31st March 2016	Nine Months Ended 31st March 2017	Corresponding Nine Months Ended 31st March 2016	Previous Year Ended 30th June 2016
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1 Revenue from operations	60113	66559	55977	188922	178686	234915
2 Other income	2315	2081	2363	6647	6543	8761
3 <b>Total income (1+2)</b>	<b>62428</b>	<b>68640</b>	<b>58340</b>	<b>195569</b>	<b>185229</b>	<b>243676</b>
4 <b>Expenses</b>						
a) Cost of raw and packing materials consumed	14933	18170	14096	46692	41566	56198
b) Purchase of stock-in-trade	8437	8187	7901	27116	27680	33350
c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	390	(2981)	198	(1634)	796	(1071)
d) Excise duty	2726	2235	1598	7169	4505	7376
e) Employee benefits expense	3346	2738	2631	9852	8800	11786
f) Finance costs	133	425	74	601	518	600
g) Depreciation expense	1419	1318	1238	4008	3927	5167
h) Advertising & sales promotion expenses	5401	5439	5245	17033	16002	20057
i) Other expenses	9505	9911	10971	29343	34681	46687
<b>Total expenses</b>	<b>46290</b>	<b>45442</b>	<b>43952</b>	<b>140180</b>	<b>138475</b>	<b>180150</b>
5 <b>Profit before tax (3-4)</b>	<b>16138</b>	<b>23198</b>	<b>14388</b>	<b>55389</b>	<b>46754</b>	<b>63526</b>
6 <b>Tax expense</b>						
a) Current tax	6644	8424	3977	20811	15781	21728
b) Deferred tax	(469)	(288)	705	(891)	(340)	(436)
	6175	8136	4682	19920	15441	21292
7 <b>Profit for the period (5-6)</b>	<b>9963</b>	<b>15062</b>	<b>9706</b>	<b>35469</b>	<b>31313</b>	<b>42234</b>
8 <b>Other comprehensive income</b>						
Other comprehensive income not to be reclassified to profit or loss:						
Re-measurement of the defined benefit plans	(36)	13	(44)	(133)	(133)	(178)
Income tax effect	13	(5)	15	46	46	62
<b>Total other comprehensive income for the year</b>	<b>(23)</b>	<b>8</b>	<b>(29)</b>	<b>(87)</b>	<b>(87)</b>	<b>(116)</b>
9 <b>Total comprehensive income for the year (7+8)</b>	<b>9940</b>	<b>15070</b>	<b>9677</b>	<b>35382</b>	<b>31226</b>	<b>42118</b>
10 Paid-up equity share capital (Face Value ₹ 10 per equity share)	3246	3246	3246	3246	3246	3246
11 Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year						161932
12 <b>Earnings per Share (Face value of ₹ 10 per equity share) (not annualised) :</b>						
a) Basic	30.69	46.40	29.90	109.27	96.47	130.11
b) Diluted	30.69	46.40	29.90	109.27	96.47	130.11
See accompanying notes to the financial results						







**Procter & Gamble Hygiene  
and Health Care Limited**  
CIN : L24239MH1964PLC012971  
Registered Office  
P&G Plaza  
Cardinal Gracias Road, Chakala  
Andheri (E), Mumbai 400 099  
(91 - 22) 2826 6000 phone  
(91 - 22) 2826 7303 fax  
www.pg.com/en\_IN/

**Notes :**

- The above results were approved by the Board of Directors of the Company at the Board Meeting held on 5th May, 2017. In compliance with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, a limited review of the above results has been carried out by the Statutory Auditors.
- The financial results of the Company have been prepared in accordance with Indian Accounting Standard (IND AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) Rules, 2016. The Company adopted IND AS from 1st July, 2016, and accordingly, these financial results (including for all the periods presented) have been prepared in accordance with the recognition and measurement principles in IND AS 34 - Interim Financial Reporting, prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. The date of transition to IND AS is July 1, 2015. The impact of the transition has been accounted for in opening reserves and the comparable periods / preceding year end have been restated accordingly.
- A reconciliation of the financial results to those reported under Previous Generally Accepted Accounting Principles (GAAP) are summarise as follows:

(₹ in Lakhs)

Particulars	Notes	Profit Reconciliation		
		Three Months Ended 31st March 2016	Nine Months Ended 31st March 2016	Year Ended 30th June 2016
<b>Profit after tax as reported under previous GAAP</b>		<b>9 730</b>	<b>31 378</b>	<b>42 318</b>
1) Change in accounting of group share based payment arrangements which were erstwhile accounted as expense when re-charged by the group, now accounted as equity settled scheme over the vesting period	(a)	( 80)	( 232)	( 306)
2) Reclassification of actuarial (gains) / losses, arising in respect of defined benefit plans		44	133	178
3) Deferred Tax Impact		12	34	44
<b>Profit after tax as reported under Ind AS</b>		<b>9 706</b>	<b>31 313</b>	<b>42 234</b>
Other comprehensive income (net of tax)		( 29)	( 87)	( 116)
<b>Total Comprehensive income as reported under Ind AS</b>		<b>9 677</b>	<b>31 226</b>	<b>42 118</b>

(a) Under Ind AS, the cost of P&G USA Stock Options is recognised based on the fair value of the options as on the grant date. In terms of the exemptions, the fair value of unvested options as at the date of transition have been accounted for as part of reserves. The fair value of options vesting after the transition date have been recognised in profit or loss.

- The Company has identified Health and Hygiene Products as its only primary reportable segment in accordance with the requirements of IND AS 108 - Operating Segments. Accordingly no separate segment information has been provided
- The Board of Directors at its meeting held on May 5, 2017 has declared an interim dividend of Rs. 362 per equity share (nominal value of Rs. 10 per equity share) aggregating to Rs. 117508 lakhs. The corporate dividend distribution tax on the said dividend amounts to Rs. 23925 lakhs

For and on behalf of the Board of Directors of  
Procter & Gamble Hygiene and Health Care Limited

Al Rajwani  
Managing Director

Place : Mumbai  
Date : 5<sup>th</sup> May, 2017







**Procter & Gamble Hygiene  
and Health Care Limited**  
CIN: L24239MH1964PLC012971  
Registered Office:  
P&G Plaza  
Cardinal Gracias Road, Chakala  
Andheri (E), Mumbai 400 099  
Tel: (91-22) 2826 6000  
Fax: (91-22) 2826 7303  
[www.pg.com/en\\_IN](http://www.pg.com/en_IN)

## **Procter & Gamble Hygiene and Health Care Ltd. Announces Third Quarter Results**

*Sales up 7%; PAT up 3% for quarter ended March 31, 2017*

**Mumbai, May 5, 2017** – Procter & Gamble Hygiene and Health Care Ltd. (PGHHCL) announced today its financial results for the quarter ended March 31, 2017. The company delivered sales of Rs. 601 crores, up 7% versus last year. Profit After Tax (PAT) was at Rs. 100 crores, up 3% versus year ago with continued focus on balanced growth.

The Board of Directors declared a special interim dividend of Rs. 362 on every equity share of Rs. 10 from accumulated surplus from profits of earlier years and the current year. The record date for the dividend will be May 18, 2017. The company has consistently delivered balanced growth in recent years behind brand fundamentals, strength of product portfolio and improved in-store execution. This year, the company also completed three decades of local manufacturing in India for its flagship brand *Whisper*. The dividend demonstrates the company's intent to reward shareholders for strong results in a competitive market environment.

About Procter & Gamble Hygiene and Health Care Ltd.

Procter & Gamble Hygiene and Health Care Ltd. (PGHHCL) is one of India's fastest growing FMCG companies that has in its portfolio WHISPER – India's leading Feminine Hygiene brand, and VICKS – India's No. 1 Health Care brand and Old Spice. The Company has carved a reputation for delivering high quality, value-added products to meet the needs of consumers. PGHHCL is committed to making every day in the lives of Indian consumers better through the quality of its products and the sincerity of its service. Please visit [www.pg.com](http://www.pg.com) for the latest news and in-depth information about P&G and its brands.

**For details contact:**

**Madison Public Relations:**

Malika Bhavnani +91 9820496099; [malika.bhavnani@madisonpr.in](mailto:malika.bhavnani@madisonpr.in)

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF Procter & Gamble Hygiene and Health Care Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Procter & Gamble Hygiene and Health Care Limited** ("the Company") for the Quarter and Nine Months ended March 31, 2017 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting ("Ind AS 34")", prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DELOITTE HASKINS & SELLS LLP  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)

Shyamak R Tata  
Partner  
(Membership No. 038320)

 MUMBAI, May 05, 2017